Pfizer expects to sell about $15 billion in coronavirus vaccine doses in 2021, according to the company’s press release. The drugmaker forecasts its revenue to be in the range of $59.4 billion and $61.4 billion this year.
- Pfizer raised its full-year earnings guidance to between $3.10-3.20, up from $3-3.10.
- In the fourth quarter, Pfizer recorded a revenue of $11.68 billion, up from the expected $11.43 billion, and above $10.44 billion during the same quarter last year.
- The company recorded earnings per share of 42 cents, down from the expected 48 cents per share.
- Pfizer expects to deliver 200 million doses of its two-shot vaccine to the U.S. by July 31 and enlisted French drugmaker Sanofi to help produce the doses.
- Pfizer is also “prepared to respond” to COVID variants since the available vaccines may not be effective in guarding against the new strains.
- Currently, Pfizer is developing a booster shot to protect against the new coronavirus variants.
Pfizer stock is currently declining. PFE: NYSE is down 2.88%
